Skip to Content



PDF options:  View Fullscreen   Download PDF

PDF Transcript

date:24-okt-17 15:48:48

Solu-Medrone may be prescribed to treat conditions other
than those listed above.
Talk to your doctor if you are unsure why you have been
given this medicine, if you do not feel better or if you feel

Package leaflet:
Information for the patient

Text Free area

40 mg, 125 mg, 500 mg, 1 gram

inks on file

Do not use this insertformat for Trobicin

methylprednisolone sodium succinate

2. What you need to know before you are given
Do not use Solu-Medrone:


Read all of this leaflet carefully before you start
taking this medicine because it contains important
information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or
• If you get any side effects, talk to your doctor or
pharmacist. This includes any possible side effects not
listed in this leaflet. See section 4.
What is in this leaflet
1. What Solu-Medrone is and what it is used for
2. What you need to know before you are given
3. How Solu-Medrone is given to you
4. Possible side effects
5. How to store Solu-Medrone
6. Contents of the pack and other information

• If you think you have ever suffered an allergic reaction,
or any other type of reaction after being given
Solu-Medrone, or any other medicine containing a
corticosteroid or any of the ingredients in this medicine
(listed in section 6). An allergic reaction may cause a
skin rash or reddening, swollen face or lips or shortness
of breath
• If you have any known or suspected allergy to cow’s milk
or its components or other dairy products, tell your
doctor before taking this medicine as it may contain
trace amounts of milk ingredients.
• If you have a widespread fungal infection (such as
thrush) which is not being treated.
• If you have recently had, or are about to have any
• If you are suffering from, or receiving treatment for,
swelling of the brain, due to malaria.
• If you are suffering from a traumatic brain injury or
See your doctor immediately if any of the above
applies to you.
Warnings and precautions
Talk to your doctor or pharmacist before taking this medicine
if you have any of the following conditions.

1. What Solu-Medrone is and what it is used for
Solu-Medrone contains methylprednisolone sodium
succinate. Methylprednisolone belongs to a group of
medicines called corticosteroids (steroids). Corticosteroids
are produced naturally in your body and are important for
many body functions.
Boosting your body with extra corticosteroid such as
Solu-Medrone can help following surgery (e.g. organ
transplants), flare-ups of the symptoms of multiple
sclerosis or other stressful conditions.
These include inflammatory or allergic conditions affecting the:
• brain caused by a tumour or tuberculosis meningitis
• bowel and gut e.g. ‘Crohn’s disease’ and ‘ulcerative
• lungs caused by asthma, severe allergy or
hypersensitivity, tuberculosis or breathing in
(aspirating) vomit or stomach contents
• skin e.g. Stevens-Johnson Syndrome.

Your doctor may have to monitor your treatment more
closely, alter your dose or give you another medicine.
• Chickenpox, measles, shingles or a herpes eye
infection. If you think you have been in contact with
someone with chickenpox, measles or shingles and you
have not already had these illnesses, or if you are unsure
if you have had them.
• Worm infestation (e.g. threadworm).
• Severe depression or manic depression (bipolar
disorder). This includes having had depression before
while taking steroid medicines like Solu-Medrone, or
having a family history of these illnesses.
• Diabetes (or if there is a family history of diabetes).
• Epilepsy, fits or seizures.
• Glaucoma (increased pressure in the eye) or if there is
a family history of glaucoma.
• You have recently suffered a heart attack.
• Heart problems, including heart failure or infections.
• Hypertension (high blood pressure).
• Hypothyroidism (an under-active thyroid).
• Joint infection.
• Kaposi’s sarcoma (a type of skin cancer).
• Kidney or liver disease.

Process structure

• Muscle problems (pain or weakness) have happened
while taking steroid medicines in the past.
• Myasthenia gravis (a condition causing tired and weak
• Osteoporosis (brittle bones).
• Pheochromocytoma (a rare tumour of adrenal gland
tissue. The adrenal glands are located above the kidneys).
• Skin abscess.
• Stomach ulcer, diverticulitis (inflammation of the bowel
wall) or other serious stomach or intestinal problems.
• Thrombophlebitis - vein problems due to thrombosis
(clots in the veins) resulting in phlebitis (red, swollen and
tender veins).
• Tuberculosis (TB) or if you have suffered tuberculosis
in the past.
• Unusual stress.
• Cushing’s disease (condition caused by an excess of
cortisol hormone in your body).
• Acute pancreatitis (inflammation of the pancreas).
Solu-Medrone should not be used in the treatment of septic
Solu-Medrone 40mg contains cow’s milk proteins
If you are allergic or suspected to be allergic to cow’s milk,
you must not be given this medicine as it may contain trace
amounts of cow’s milk proteins. Serious allergic reactions
have occurred in patients allergic to cow’s milk.
Other medicines and Solu-Medrone
Tell your doctor or pharmacist if you are taking, have
recently taken or might take any other medicines (including
any you have obtained without a prescription).
This could be harmful or affect the way Solu-Medrone or the
other medicine works:
• Acetazolamide - used to treat glaucoma and epilepsy
• Aminoglutethimide or Cyclophosphamide – used for
treating cancer
• Anticoagulants - used to ‘thin’ the blood such as
acenocoumarol, phenindione and warfarin
• Anticholinesterases - used to treat myasthenia gravis
(a muscle condition) such as distigmine and neostigmine
• Antibiotics (such as erythromycin, clarithromycin or
• Antidiabetics – medicines used to treat high blood sugar
• Antihypertensives – medicines used to lower blood
• Aprepitant and Fosaprepitant – used to prevent
nausea and vomiting
• Aspirin and non-steroidal anti-inflammatory medicines
(also called NSAIDs) such as ibuprofen used to treat
mild to moderate pain
• Barbiturates, carbamazepine, phenytoin and
primidone – used to treat epilepsy
• Carbenoxolone and cimetidine - used for heartburn
and acid indigestion
• Ciclosporin - used to treat conditions such as severe
rheumatoid arthritis, severe psoriasis or following an
organ or bone marrow transplant

• Digoxin - used for heart failure and/or an irregular heart
• Diltiazem or mibefradil – used for heart problems or
high blood pressure
• Ethinylestradiol and norethisterone – an oral
• Antivirals (such as ritonavir, indinavir) and
pharmacokinetic enhancers (such as cobicistat) used
to treat HIV infections
• Isoniazid - used to treat bacterial infections
• Ketoconazole or itraconazole – used to treat fungal
• Mifepristone – used for the medical termination of a
• Pancuronium or vercuronium – or other medicines
called neuromuscular blocking agents which are used in
some surgical procedures
• Potassium depleting agents – such as diuretics
(sometimes called water tablets), amphotericin B,
xanthenes or beta2 agonists (e.g. medicines used to
treat asthma)
• Rifampicin and rifabutin – antibiotics used to treat
tuberculosis (TB)
• Tacrolimus – used following an organ transplant to
prevent rejection of the organ
• Vaccines - tell your doctor or nurse if you have recently
had, or are about to have any vaccination. You should
not have ‘live’ vaccines while using this medicine. Other
vaccines may be less effective.

Driving and using machines
Undesirable effects, such as dizziness, vertigo, visual
disturbances and fatigue are possible after treatment with
corticosteroids. If you are affected do not drive or operate

3. How Solu-Medrone is given to you
Steroid Cards
Remember to always carry a Steroid Treatment Card.
Make sure your doctor or pharmacist has filled out
the details of your medicine, including the dose and
how long you will require steroid treatment.
You should show your steroid card to anyone who gives
you treatment (such as a doctor, nurse or dentist) while
you are taking this medicine, and for 3 months after your
last injection.
If you are admitted to hospital for any reason always tell
your doctor or nurse that you are taking Solu-Medrone.
You can also wear a medic-alert bracelet or pendant to let
medical staff know that you are taking a steroid if you
have an accident or become unconscious.
Dosage information
Your doctor will decide on the site of injection, how much of
the medicine and how many injections you will receive
depending on the condition being treated and its severity.
Your doctor will inject you with the lowest dose for the
shortest possible time to get effective relief of your symptoms.

If you are taking long term medication(s)
If you are being treated for diabetes, high blood pressure or
water retention (oedema) tell your doctor as he/she may
need to adjust the dose of the medicines used to treat these

Solu-Medrone will be given as an injection by your doctor
or nurse, either into a vein (intravenous) or into a muscle
(intramuscular). Usually the first dose is given into a vein,
especially in an emergency.

Before you have any operation, tell your doctor, dentist or
anaesthetist that you are taking Solu-Medrone.

It will be given slowly over at least 5 minutes. For larger
doses this may take 30 minutes or more. Large doses
should normally be used for only two to three days.

If you require a test to be carried out by your doctor or
in hospital it is important that you tell the doctor or nurse
that you are taking Solu-Medrone. This medicine can affect
the results of some tests.
Solu-Medrone with drink
Do not drink grapefruit juice while taking this medicine.
Pregnancy and breast-feeding
If you are pregnant, think you may be pregnant or are
planning to have a baby, ask your doctor or pharmacist for
advice before taking this medicine, as it could slow the
baby’s growth.There is a risk of low birth weight of a baby;
this risk can be minimised by taking the lowest effective
dose of the corticosteroids.

The medicine is first dissolved in Sterile Water for
Injections. If the medicine is to be given by infusion (using
a pump or drip) it is then mixed with another suitable fluid.
No other medicines should be mixed with it.
Treatment will normally be the same as for younger adults.
However your doctor may want to see you more regularly to
check how you are getting on with this medicine.
Children and adolescents
Corticosteroids can affect growth in children so your
doctor will prescribe the lowest dose that will be effective
for your child.

Cataracts have been observed in infants born to mothers
undergoing long-term treatment with corticosteroids during

If you are given more Solu-Medrone than you should
If you think you have been given too many injections of
Solu-Medrone please speak to your doctor immediately.

If you are breast-feeding, ask your doctor or pharmacist for
advice, as small amounts of corticosteroid medicines may
get into breast milk.

Stopping/reducing the dose of your Solu-Medrone
Your doctor will decide when it is time to stop your

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------The following information is intended for healthcare
professionals only:

40 mg, 125 mg, 500 mg, 1 gram
methylprednisolone sodium succinate

Process Black

For further information consult the SPC (Summary
of Product Characteristics).
Posology and method of administration
Solu-Medrone may be administered intravenously or
intramuscularly, the preferred method for emergency use
being intravenous injection given over a suitable time
interval. When administering Solu-Medrone in high doses
intravenously, it should be given over a period of at least
30 minutes. Doses up to 250 mg should be given
intravenously over a period of at least five minutes.







For intravenous infusion the initially prepared solution may
be diluted with 5% dextrose in water, isotonic saline
solution, or 5% dextrose in isotonic saline solution. To avoid
compatibility problems with other drugs, Solu-Medrone
should be administered separately, only in the solutions
Undesirable effects may be minimised by using the lowest
effective dose for the minimum period (see section 4.4 of the
Parenteral drug products should wherever possible be
visually inspected for particulate matter and discoloration
prior to administration.
Adults: Dosage should be varied according to the severity of
the condition, initial dosage will vary from 10 to 500 mg. In
the treatment of graft rejection reactions following
transplantation, a dose of up to 1 g/day may be required.
Although doses and protocols have varied in studies using
methylprednisolone sodium succinate in the treatment of


24-okt-17 EA



graft rejection reactions, the published literature supports the
use of doses of this level, with 500 mg to 1 g most
commonly used for acute rejection. Treatment at these
doses should be limited to a 48-72 hour period until the
patient’s condition has stabilised, as prolonged high dose
corticosteroid therapy can cause serious corticosteroid
induced side-effects (see sections 4.4 and 4.8 of the SPC).

Elderly patients: Solu-Medrone is primarily used in acute
short-term conditions. There is no information to suggest
that a change in dosage is warranted in the elderly.
However, treatment of elderly patients should be planned
bearing in mind the more serious consequences of the
common side-effects of corticosteroids in old age and close
clinical supervision is required (see section 4.4 of the SPC).

Children and adolescents: In the treatment of high dose
indications, such as haematological, rheumatic, renal and
dermatological conditions, a dosage of 30 mg/kg/day to a
maximum of 1 g/day is recommended. This dosage may be
repeated for three pulses either daily or on alternate days. In
the treatment of graft rejection reactions following
transplantation, a dosage of 10 to 20 mg/kg/day for up to
3 days, to a maximum of 1 g/day, is recommended. In the
treatment of status asthmaticus, a dosage of 1 to
4 mg/kg/day for 1-3 days is recommended.

Detailed recommendations for adult dosage are as follows:
In anaphylactic reactions adrenaline or noradrenaline
should be administered first for an immediate
haemodynamic effect, followed by intravenous injection of
Solu-Medrone (methylprednisolone sodium succinate) with
other accepted procedures. There is evidence that
corticosteroids through their prolonged haemodynamic effect
are of value in preventing recurrent attacks of acute
anaphylactic reactions.
In sensitivity reactions Solu-Medrone is capable of
providing relief within one half to two hours. In patients with
status asthmaticus, Solu-Medrone may be given at a dose of

40 mg intravenously, repeated as dictated by patient
response. In some asthmatic patients it may be
advantageous to administer by slow intravenous drip over
a period of hours.
In graft rejection reactions following
transplantation doses of up to 1 g per day have been
used to suppress rejection crises, with doses of 500 mg
to 1 g most commonly used for acute rejection. Treatment
should be continued only until the patient’s condition has
stabilised; usually not beyond 48-72 hours.
In cerebral oedema corticosteroids are used to reduce
or prevent the cerebral oedema associated with brain
tumours (primary or metastatic).
In patients with oedema due to tumour, tapering the dose
of corticosteroid appears to be important in order to avoid
a rebound increase in intracranial pressure. If brain
swelling does occur as the dose is reduced (intracranial
bleeding having been ruled out), restart larger and more
frequent doses parenterally. Patients with certain


You will need to come off this medicine slowly to avoid
withdrawal symptoms. These symptoms may include
itchy skin, fever, muscle and joint pains, runny nose,
sticky eyes, sweating and weight loss.
If your symptoms seem to return or get worse as your
dose of this medicine is reduced tell your doctor
Mental problems while taking Solu-Medrone
Mental health problems can happen while taking steroids
like Solu-Medrone (see section 4).
• These illnesses can be serious.
• Usually they start within a few days or weeks of
starting the medicine.
• They are more likely to happen at high doses.
• Most of these problems go away if the dose is lowered
or the medicine is stopped. However if the problems
do happen they might need treatment.
Talk to a doctor if you (or someone using this medicine)
shows any signs of mental problems. This is particularly
important if you are depressed, or might be thinking about
suicide. In a few cases mental problems have happened
when doses are being lowered or stopped.
If you have any further questions on the use of this
medicine, ask your doctor or pharmacist.

4. Possible side effects
Like all medicines, this medicine can cause side effects,
although not everybody gets them. Your doctor will have
given you this medicine for a condition which if not treated
properly could become serious.
In certain medical conditions medicines like
Solu-Medrone (steroids) should not be stopped
abruptly. If you suffer from any of the following
symptoms seek IMMEDIATE medical attention. Your
doctor will then decide whether you should
continue taking your medicine:
• Allergic reactions, such as skin rash, swelling of the
face or wheezing and difficulty breathing. This type of
side effect is rare, but can be serious.
• Pancreatitis, stomach pain spreading to your back,
possibly accompanied by vomiting, shock and loss of

• Burst or bleeding ulcers, symptoms of which are
stomach pain (especially if it seems to spread to your
back), bleeding from the back passage, black or
bloodstained stools and/or vomiting blood.
• Infections. This medicine can hide or change the signs
and symptoms of some infections, or reduce your
resistance to the infection, so that they are hard to
diagnose at an early stage. Symptoms might include a
raised temperature and feeling unwell. Symptoms of a
flare up of a previous TB infection could be coughing
blood or pain in the chest. Symptoms of a previous
malaria infection could involve chills and fever.
Solu-Medrone may also make you more likely to develop
a severe infection.
• Pulmonary embolus (blood clots in the lung),
symptoms include sudden sharp chest pain,
breathlessness and coughing up blood.
• Raised pressure within the skull of children
(pseudotumour cerebri) symptoms of which are
headaches with vomiting, lack of energy and drowsiness.
This side effect usually occurs after treatment is
• Thrombophlebitis (blood clots or thrombosis in a leg
vein), symptoms of which include painful swollen, red
and tender veins.
If you experience any of the following side effects, or
notice any other unusual effects not mentioned in this
leaflet, tell your doctor straight away.
The side effects may occur with certain frequencies, which
are defined as follows:
• not known: frequency cannot be estimated from the
available data.
Blood, heart and circulation
not known
• High blood pressure, symptoms of which are headaches,
or generally feeling unwell.
• Problems with the pumping of your heart (heart failure)
symptoms of which are swollen ankles, difficulty in
breathing and palpitations (awareness of heart beat) or
irregular beating of the heart, irregular or very fast or
slow pulse.
• Low blood pressure symptoms may include dizziness,
fainting, lightheadedness, blurred vision, a rapid, or
irregular heartbeat (palpitations), general weakness.
• Increased numbers of white blood cells (leukocytosis).
Body water and salts
not known
• Swelling and high blood pressure, caused by increased
levels of water and salt content.
• Cramps and spasms, due to the loss of potassium from
your body. In rare cases this can lead to congestive heart
failure (when the heart cannot pump properly).
Digestive system
not known
• Ulcers.
• Nausea (feeling sick) or vomiting (being sick).
• Diarrhoea.

Thrush in the gullet (discomfort on swallowing).
Bloated stomach.
Abdominal pain.

not known
• A feeling of dizziness or spinning (vertigo).
not known
• Cataracts (indicated by failing eyesight).
• Glaucoma (raised pressure within the eye, causing pain
in the eyes and headaches).
• Swollen optic nerve (papilloedema, indicated by sight
• Thinning of the clear part at the front of the eye (cornea)
or of the white part of the eye (sclera).
• Worsening of viral or fungal eye infections.
• Protruding of the eyeballs (exophthalmos).
• Blurred vision (chorioretinopathy).
General disorders
not known
• Poor wound healing.
• Feeling tired or unwell.
• Skin reactions at the site of injection.
Hormones and metabolic system
not known
• Slowing of normal growth in infants, children and
adolescents which may be permanent.
• Round or moon-shaped face (Cushingoid facies).
• Irregular or no periods in women.
• Increased appetite and weight gain.
• Diabetes or worsening of existing diabetes.
• Prolonged therapy can lead to lower levels of some
hormones which in turn can cause low blood pressure
and dizziness. This effect may persist for months.
• The amount of certain chemicals (enzymes) called
alanine transaminase, aspartate transaminase and
alkaline phosphatase that help the body digest drugs and
other substances in your body may be raised after
treatment with a corticosteroid. The change is usually
small and the enzyme levels return to normal after your
medicine has cleared naturally from your system. You
will not notice any symptoms if this happens, but it will
show up if you have a blood test.
• Accumulation of fat tissue on localised parts of the body,
manifesting as different presentations for example back
pain or weakness (due to epidural lipomatosis).
Immune system
not known
• Increased susceptibility to infections.
• Suppression of reactions to skin tests, such as that for
Muscles and bones
not known
• Brittle bones (bones that break easily).
• Muscle weakness.

• Muscle wasting.
• Broken bones or fractures.
• Breakdown of bone due to poor circulation of blood, this
causes pain in the hip.
• Torn muscle tendons causing pain and/or swelling.
• Muscle cramps or spasms.

Once the medicine has been mixed with Sterile Water
for Injections the solution should be used straight
away. Any unused liquid should be disposed of safely.

Nerves and mood issues
not known
Steroids including methylprednisolone can cause serious
mental health problems.
• Feeling depressed, including thinking about suicide.
• Feeling high (mania) or moods that go up and down.
• Feeling anxious, having problems sleeping, difficulty in
thinking or being confused and losing your memory.
• Feeling, seeing or hearing things which do not exist.
Having strange and frightening thoughts, changing how
you act or having feelings of being alone.
• Fits.

6. Contents of the pack and other

not known
• Acne.
• Bruising.
• Thinning of skin (skin atrophy).
• Stretch marks (skin striae).
• Small purple/red patches on the skin.
• Pale or darker patches on your skin, or raised patches
which are an unusual colour.
• Excessive growth of bodily and facial hair.
• Rash, itching, hives.
• Increased sweating.
Liver disorder
not known
• Methylprednisolone can damage your liver; hepatitis and
increase of liver enzymes have been reported.
Vascular disorders
not known
• Increased clotting of the blood.
If you experience any of the side effects listed above
tell your doctor straight away.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist.
This includes any possible side effects not listed in this
leaflet. You can also report side effects directly via the Yellow
Card Scheme at By reporting
side effects you can help provide more information on the
safety of this medicine.

5. How to store Solu-Medrone

Your doctor will check that the solution contains no
particles and is not discoloured before using it.

What Solu-Medrone contains
This medicine contains the following amounts of
methylprednisolone sodium succinate as the active
40 mg vial:
53 mg methylprednisolone sodium
succinate (equivalent to 40 mg
125 mg vial: 165.8 mg methylprednisolone
sodium succinate (equivalent to
125 mg methylprednisolone)
500 mg vial: 663 mg methylprednisolone sodium
succinate (equivalent to 500 mg
1 g vial:
1.326 g methylprednisolone sodium
succinate (equivalent to 1 g

Text Free area

You will need to come off this treatment slowly if you:
• have had repeated doses of corticosteroids for more
than 3 weeks
• have been given high doses of Solu-Medrone, over
32 mg daily, even if it was only for 3 weeks or less
• have already had a course of corticosteroid tablets or
injections in the last year
• already had problems with your adrenal glands
(adrenocortical insufficiency) before you started this

Solu-Medrone also contains the inactive ingredients
sodium biphosphate and sodium phosphate.
The 40 mg vial also contains lactose monohydrate
produced from cow’s milk (see section 2, Do not use
What Solu-Medrone looks like and contents of
the pack
Solu-Medrone is a powder which comes in a clear
glass vial fitted with a rubber stopper. Each pack also
contains a vial of Sterile Water for Injections.
Marketing Authorisation Holder
Pfizer Limited, Ramsgate Road, Sandwich,
Kent CT13 9NJ, UK.
Pharmacia NV/SA, Rijksweg 12, B-2870, Puurs, Belgium.
Company Contact Address
For further information on your medicine contact Medical
Information at Pfizer Limited, Walton Oaks, Dorking Road
Tadworth, Surrey, KT20 7NS.
Tel: 01304 616161.
This leaflet was last revised in 09/2017
Ref: SM 18_0

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated
on the label and carton after EXP. The expiry date refers to
the last day of that month.
This medicine must be stored below 25°C.

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------malignancies may need to remain on oral corticosteroid
therapy for months or even life. Similar or higher doses
may be helpful to control oedema during radiation therapy.

Process Black

The following are suggested dosage schedules for
oedemas due to brain tumour.
Schedule A (1) Dose (mg) Route Interval
in hours
Pre-operative: 20
During Surgery: 20 to 40
Post-operative: 20


24 hours
24 hours
24 hours
24 hours
24 hours
24 hours
24 hours

Schedule B (2) Dose (mg) Route Interval
in hours
Pre-operative: 40
Post-operative: 40
Oral 6
Oral 6
Oral 8
Oral 12


Aim to discontinue therapy after a total of 10 days.
In the treatment of acute exacerbations of multiple sclerosis
in adults, the recommended dose is 1 g daily for 3 days.
Solu-Medrone should be given as an intravenous infusion
over at least 30 minutes.

In hepatobiliary effects drug induced liver injury including
acute hepatitis or liver enzyme increase can result from
cyclical pulsed IV methylprednisolone (usually at initial dose
≥ 1 g/day). Rare cases of hepatotoxicity have been reported.
The time to onset can be several weeks or longer. In the
majority of case reports resolution of the adverse events has
been observed after treatment was discontinued. Therefore,
appropriate monitoring is required.
In other indications, initial dosage will vary from 10 to
500 mg depending on the clinical problem being treated.
Larger doses may be required for short-term management of
severe, acute conditions. The initial dose, up to 250 mg,
should be given intravenously over a period of at least
5 minutes, doses exceeding 250 mg should be given
intravenously over a period of at least 30 minutes.

Subsequent doses may be given intravenously or
intramuscularly at intervals dictated by the patient’s
response and clinical condition. Corticosteroid therapy is an
adjunct to, and not replacement for, conventional therapy.
The shelf-life is printed on labels and cartons. Do not use
Solu-Medrone after this date. After reconstitution with Sterile
Water for Injections, use immediately, discard any
Storage of the product
Store below 25°C. Refer to Posology and method of
administration section above. No diluents other than those
referred to are recommended. Parenteral drug products
should be inspected visually for particulate matter and
discoloration prior to administration.
Ref: SM 16_1








24-okt-17 EA



+ Expand Transcript

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.